查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006212

蛋白酪氨酸激酶抑制劑市場：2026-2032年全球市場預測（依適應症、標靶、代數、給藥途徑及分銷通路分類）

Tyrosine Kinase Inhibitors Market by Indication, Target, Generation, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，蛋白酪氨酸激酶抑制劑市場價值將達到 682.1 億美元，到 2026 年將成長至 733.6 億美元，到 2032 年將達到 1,117.5 億美元，複合年成長率為 7.30%。

主要市場統計數據
基準年 2025 682.1億美元
預計年份：2026年 733.6億美元
預測年份 2032 1117.5億美元
複合年成長率 (%) 7.30%

全面概述蛋白酪氨酸激酶抑制劑如何從標靶治療概念發展成為現代腫瘤學中臨床和商業性的重點。

蛋白酪氨酸激酶抑制劑透過將分子層面的見解轉化為標靶治療，從而帶來切實的臨床獲益，徹底改變了我們治療腫瘤的方式。在過去的二十年中，隨著生物標記識別技術的進步和對抗藥性機制理解的加深，這些藥物已從實驗性治療發展成為多種腫瘤類型的核心療法。儘管隨著新一代抑制劑的不斷問世和患者選擇標準的不斷完善，臨床療效持續改善，但競爭格局也變得更加複雜，因為如今藥物的差異化取決於耐受性、抗藥性光譜以及聯合治療的潛力。

科學進步、適應性臨床試驗設計、支付方期望和供應鏈韌性如何重新定義蛋白酪氨酸激酶抑制劑生態系統。

蛋白酪氨酸激酶抑制劑領域正經歷一系列變革，這些變革正在重新定義產品的開發、定位和獲取途徑。科學進步加速了新型有效標靶的發現，並不斷催生出旨在克服標靶抗藥性和中樞神經系統穿透性等挑戰的新一代藥物。同時，臨床開發也變得更加迭代。籃式試驗和傘式試驗、適應性通訊協定以及真實世界數據（RWE）的整合正在縮短假設檢驗週期，並促成更動態的「啟動/停止」決策。

評估 2025 年美國關稅變化如何重塑癌症藥物生產中的供應鏈韌性、籌資策略和成本管理。

美國提案於2025年實施的關稅措施對全球抗癌藥物生產供應鏈產生了複雜的影響，尤其對蛋白酪氨酸激酶抑制劑、活性藥物成分和關鍵成分的供應造成了衝擊。跨境採購中間體和成品的製造商面臨潛在的成本壓力，這種壓力會波及採購、契約製造和分銷等各個環節。為了應對這些壓力，許多公司正在探索供應商地域多元化、更多地利用本地或近岸製造夥伴關係以及重新談判長期供應契約，以維持盈利能力和供應的連續性。

詳細的細分分析解釋了適應症、分子標靶、世代、給藥途徑和分銷管道如何相互交織並塑造產品策略。

細分市場洞察揭示了治療重點、基於機制的標靶和給藥策略的交匯點，從而影響臨床開發和商業化策略。基於適應症，本研究對乳癌、慢性骨髓性白血病、非小細胞肺癌和腎細胞癌的市場進行了分析。慢性骨髓性白血病進一步細分為第一線、第二線和第三線治療方案。同樣，非小細胞肺癌也細分為第一線、第二線和三線治療方案。這些基於適應症的區分至關重要，因為固體癌和骨髓惡性腫瘤在臨床終點預期、競爭格局和標準治療順序方面存在顯著差異，從而影響試驗設計和適應症策略。

區域監管差異、支付方趨勢和當地生產重點，使得蛋白酪氨酸激酶抑制劑的開發和取得需要採取差異化的全球策略。

區域趨勢對蛋白酪氨酸激酶抑制劑的臨床開發優先順序、監管合作和商業化路徑有顯著影響，因此，制定有效的全球策略必須具備區域觀點。在美洲，儘管監管機構維持著快速核准機制，但支付方越來越要求提供強力的衛生經濟學證據和結果數據以支持報銷，這推動了早期衛生技術評估的開展和真實世界數據（RWE）項目的擴展。在歐洲、中東和非洲（EMEA），監管環境的異質性和支付方能力的差異，使得個人化的市場進入、區域夥伴關係和靈活的定價策略成為必要，以促進跨多個司法管轄區的報銷和競標流程。在亞太地區，快速的病患招募能力、新興的國家創新生態系統和多樣化的法規結構，既為快速商業化提供了機遇，也帶來了複雜的在地化調整的必要性。在生產和技術轉移能夠帶來競爭優勢的地區，這一趨勢尤其明顯。

策略競爭行為和夥伴關係模式推動標靶癌症療法的產品差異化、產品線優先排序和商業化效率。

蛋白酪氨酸激酶抑制劑領域製藥和生物技術公司的競爭行為反映出對持續創新和最佳化商業性執行的高度重視。主要企業日益優先研發旨在克服抗藥性突變和提高耐受性的下一代分子，而中型和新興企業則傾向於瞄準特定適應症或基於生物標記定義的患者群體，以建立穩固的市場地位。創新者與合約開發組織（CDO）之間的合作仍然是加速規模化生產和維持生產柔軟性的關鍵，而授權協議仍然是確保區域商業化和市場准入的有效途徑。

為腫瘤領域的產業領導者提供可操作的策略步驟，以加強產品組合重點、供應鏈韌性、證據產生和商業化準備。

在蛋白酪氨酸激酶抑制劑領域不斷演變的格局中，產業領導者應採取一系列切實有效的措施，將科學差異化與營運準備相結合，以確保臨床和商業性效益。首先，為最大限度降低後期重新定位的風險，應優先考慮將新一代分子設計與明確的臨床定位和抗藥性管理策略相結合的產品組合決策。其次，透過原料藥(API) 和組件來源多元化、盡可能投資雙重採購以及擴大近岸生產選擇，增強供應鏈韌性並降低關稅和地緣政治風險。第三，將價值驗證儘早納入研發計劃，透過將衛生經濟學終點、真實世界數據 (RWD) 收集和患者報告結局 (PRO) 納入註冊和上市後監測，為與支付方的談判和基於價值的合約提供支援。

一種透明且可重複的調查方法，結合了初步訪談、文獻整合、專利和臨床研發管線分析以及基於情境的洞察三角驗證。

本分析的調查方法結合了定性和定量方法，將臨床、監管和商業資訊整合為可操作的見解。主要研究包括對臨床研究人員、監管專家、支付方顧問和供應鏈高管進行結構化訪談，以獲取關於試驗設計偏好、報銷預期和營運限制的第一手觀點。次要研究則仔細審查了同行評審文獻、監管指導文件、臨床試驗註冊信息和上市公司資訊披露，以全面檢驗發展趨勢和過往監管先例。專利格局分析和臨床研發管線圖譜用於評估基於機制的創新密度和競爭情況。

策略重點整合表明，腫瘤學領域的長期成功取決於科學創新、營運韌性和證據產生的結合。

總之，蛋白酪氨酸激酶抑制劑仍然是腫瘤治療領域的重要藥物類別，持續的創新既推動了新的臨床應用，也增加了策略複雜性。分子標靶療法的進步，以及對適應性試驗設計和真實世界臨床結果的重視，正在重塑藥物研發模式和商業性預期。貿易政策的變化和供應鏈的脆弱性等外部壓力，迫使製藥公司重新思考籌資策略，並將韌性融入其商業模式。同時，區域監管差異和不斷變化的支付方需求，也要求制定個人化的准入策略，以平衡全球證據的累積和在地化需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：蛋白酪氨酸激酶抑制劑市場：依適應症分類

  • 乳癌
  • 慢性骨髓性白血病
    • 第一選擇
    • 第二行
    • 第三行
  • 非小細胞肺癌
    • 第一選擇
    • 第二行
    • 第三行
  • 腎臟細胞癌

第9章：以標靶分類的蛋白酪氨酸激酶抑制劑市場

  • ALK
  • Bcr-Abl
    • 第一代
    • 第二代
    • 第三代
  • EGFR
    • 第一代
    • 第二代
    • 第三代
  • VEGFR

第10章：蛋白酪氨酸激酶抑制劑市場（按代分類）

  • 第一代
  • 第二代
  • 第三代

第11章：蛋白酪氨酸激酶抑制劑市場：依給藥途徑分類

  • 靜脈
  • 口服

第12章：蛋白酪氨酸激酶抑制劑市場：依通路分類

  • 醫院藥房
  • 零售藥房

第13章：蛋白酪氨酸激酶抑制劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：蛋白酪氨酸激酶抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：蛋白酪氨酸激酶抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國蛋白酪氨酸激酶抑制劑市場

第17章：中國蛋白酪氨酸激酶抑制劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Rigel Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-B168537796FC

The Tyrosine Kinase Inhibitors Market was valued at USD 68.21 billion in 2025 and is projected to grow to USD 73.36 billion in 2026, with a CAGR of 7.30%, reaching USD 111.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 68.21 billion
Estimated Year [2026] USD 73.36 billion
Forecast Year [2032] USD 111.75 billion
CAGR (%) 7.30%

Comprehensive overview of how tyrosine kinase inhibitors transitioned from targeted concepts to integrated clinical and commercial priorities in modern oncology

Tyrosine kinase inhibitors have reshaped the therapeutic landscape for oncology by converting molecular insights into targeted therapies that deliver tangible clinical benefit. Over the past two decades, these agents have moved from experimental therapies to cornerstone treatments in multiple tumor types, driven by increasingly precise biomarker identification and enhanced understanding of resistance mechanisms. The introduction of successive generations of inhibitors and the refinement of patient selection criteria have progressively improved clinical outcomes while simultaneously complicating competitive dynamics as differentiation now rests on tolerability, resistance profiles, and combination potential.

Today's strategic conversations emphasize not only molecule-level efficacy but also durable development pathways that integrate companion diagnostics, adaptive trial designs, and payer-driven evidence requirements. Regulatory pathways continue to evolve alongside accelerated approvals and conditional pathways, prompting developers to balance speed with the need for confirmatory evidence. As a result, stakeholders must align clinical development plans, commercial access strategies, and manufacturing capabilities to ensure that scientific advantages convert into patient access and commercial viability. Transitioning from proof-of-concept to sustainable product franchises requires cohesive cross-functional planning and nimble responses to evolving clinical and regulatory data.

How scientific advances, adaptive clinical designs, payer expectations, and supply chain resilience are collectively redefining the tyrosine kinase inhibitor ecosystem

The landscape for tyrosine kinase inhibitors is undergoing a set of transformative shifts that are redefining how products are developed, positioned, and accessed. Scientific advances have accelerated the identification of novel actionable targets and led to the proliferation of next-generation agents designed to overcome on-target resistance and central nervous system penetration challenges. Concurrently, clinical development is becoming more iterative: basket and umbrella trials, adaptive protocols, and real-world evidence integration are shortening hypothesis cycles and enabling more dynamic go/no-go decisions.

Commercially, differentiation is migrating from single-agent efficacy to a broader value proposition that includes tolerability, sequencing strategies, and combination potential with immunotherapies and other targeted agents. Payers and health systems are increasingly focused on total cost of care and longitudinal outcomes, prompting manufacturers to develop more robust evidence packages and outcomes-based agreements. Manufacturing and supply chain resilience have emerged as strategic priorities in response to geopolitical tensions and regulatory scrutiny, while digital tools and decentralized trial elements are improving patient recruitment and retention. These converging trends require a new playbook that combines deep scientific rigor with commercial agility and supply chain foresight.

Assessment of how 2025 tariff changes in the United States are reshaping supply chain resilience, sourcing strategies, and cost management for oncology drug production

Proposed and implemented tariff measures in the United States for 2025 have introduced a complex set of implications for the global supply chains underpinning oncology drug production, with particular relevance for tyrosine kinase inhibitor supply, active pharmaceutical ingredients, and key componentry. Manufacturers that source intermediates or finished dosage forms across borders face potential cost pressures that can cascade through procurement, contract manufacturing, and distribution relationships. In response, many companies are evaluating the geographic diversification of suppliers, increasing use of local or near-shore manufacturing partnerships, and renegotiation of long-term supply agreements to preserve margin and continuity of supply.

Beyond immediate cost considerations, tariffs influence strategic decisions around inventory policies, lead times, and regulatory filings tied to manufacturing sites. Firms are reassessing the resilience of single-source dependencies and accelerating investments in dual-sourcing and strategic stockpiles where feasible. Moreover, tariff-driven price pressures can intensify payer scrutiny and amplify the need for stronger pharmacoeconomic evidence to justify premium pricing for next-generation agents. In parallel, trade policy uncertainty is prompting closer collaboration between commercial, regulatory, and manufacturing teams to model scenarios, mitigate disruption risk, and align contingency plans that maintain patient access despite shifting cross-border cost structures.

In-depth segmentation analysis explaining how indication, molecular target, generation, administration route, and distribution channels converge to shape product strategy

Segmentation insights illuminate where therapeutic focus, mechanistic targeting, and delivery strategies intersect to shape clinical development and commercialization approaches. Based on Indication, market is studied across Breast Cancer, Chronic Myeloid Leukemia, Non Small Cell Lung Cancer, and Renal Cell Carcinoma. The Chronic Myeloid Leukemia is further studied across First Line, Second Line, and Third Line. The Non Small Cell Lung Cancer is further studied across First Line, Second Line, and Third Line. These indication-focused distinctions are critical because clinical endpoint expectations, competitive backdrops, and standard-of-care sequences differ markedly between solid tumors and hematologic malignancies, influencing trial design and label strategy.

Based on Target, market is studied across Alk, Bcr-Abl, EGFR, and Vegfr. The Bcr-Abl is further studied across First Generation, Second Generation, and Third Generation. The EGFR is further studied across First Generation, Second Generation, and Third Generation. Target-specific segmentation highlights how molecular selectivity and resistance profiles drive differentiation and clinical positioning, while generational distinctions reflect evolutionary design efforts to improve potency and evade resistance. Based on Generation, market is studied across First Generation, Second Generation, and Third Generation; this lens helps clarify how incremental innovations shift tolerability and sequencing narratives. Based on Route Of Administration, market is studied across Intravenous and Oral, signaling divergent development, manufacturing, and adherence considerations that affect commercial uptake. Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies, indicating where stakeholder engagement, channel economics, and patient access strategies will materially differ. Together, these segmentation dimensions provide an analytical scaffold to evaluate clinical opportunity, operational requirements, and commercial tactics across heterogeneous therapeutic contexts.

How regional regulatory diversity, payer dynamics, and local manufacturing priorities require differentiated global strategies for tyrosine kinase inhibitor development and access

Regional dynamics materially shape clinical development priorities, regulatory interactions, and commercialization pathways for tyrosine kinase inhibitors, and a region-sensitive perspective is essential to effective global strategy. In the Americas, regulatory agencies maintain accelerated approval mechanisms while payers increasingly demand robust health economic evidence and outcomes data to support reimbursement, driving early heath technology assessment engagement and expanded real-world evidence programs. In Europe, Middle East & Africa, regulatory heterogeneity and variable payer capabilities require tailored market access approaches, regional partnerships, and flexible pricing strategies to navigate reimbursement and tender processes across multiple jurisdictions. In Asia-Pacific, rapid enrollment capacities, rising domestic innovation ecosystems, and diverse regulatory frameworks create both swift commercial opportunities and complex local adaptation needs, particularly where manufacturing localization and technology transfer can support competitive positioning.

Across all regions, cross-border clinical collaboration and harmonized data generation approaches can streamline evidence development while region-specific commercialization playbooks must address distinct stakeholder landscapes, patient pathways, and distribution structures. Regulatory timelines, patient population characteristics, and healthcare financing models vary significantly, and therefore global programs must incorporate modular launch strategies that allow for concurrent but differentiated market entry plans. Adapting to regional nuances in clinical expectations and payer decision frameworks will be critical to maximizing the clinical and commercial impact of new tyrosine kinase inhibitor entrants.

Strategic competitive behaviors and partnership models that are driving product differentiation, pipeline prioritization, and commercialization effectiveness in targeted oncology therapies

Competitive behavior across pharmaceutical and biotech companies in the tyrosine kinase inhibitor space reflects an intense focus on sustaining innovation while optimizing commercial execution. Leading firms are increasingly prioritizing next-generation molecules designed to overcome resistance mutations and improve tolerability, while mid-sized and emerging companies often pursue niche indications or biomarker-defined populations to create defensible footholds. Partnerships between innovators and contract development organizations remain central to accelerating scale-up and maintaining flexibility in manufacturing, and licensing transactions continue to be a pragmatic route for regional commercialization and access.

Strategic pipelines emphasize complementary modalities such as antibody-drug conjugates, combination regimens with immunotherapies, and efforts to pair small-molecule inhibitors with precision diagnostic platforms. Business development activity focuses on securing late-stage assets or platform technologies that can be integrated into multi-line treatment sequences. At the same time, companies face increasing pressure to demonstrate value beyond clinical endpoints, necessitating investments in health economics teams, real-world evidence generation, and payer engagement capabilities. Operationally, organizations that invest early in scalable manufacturing, robust pharmacovigilance, and cross-functional launch readiness are better positioned to convert clinical differentiation into durable commercial performance.

Actionable strategic steps for industry leaders to strengthen portfolio focus, supply chain resilience, evidence generation, and commercialization readiness in oncology

To capture clinical and commercial upside in the evolving tyrosine kinase inhibitor environment, industry leaders should pursue a set of pragmatic, high-impact actions that align scientific differentiation with operational readiness. First, prioritize portfolio decisions that couple next-generation molecular design with clearly articulated clinical positioning and resistance management strategies to minimize late-stage repositioning risk. Second, fortify supply chain resilience by diversifying API and component sourcing, investing in dual-sourcing where feasible, and expanding near-shore manufacturing options to mitigate tariff and geopolitical exposure. Third, integrate value demonstration into development plans early by embedding health economic endpoints, real-world data collection, and patient-reported outcomes into registrational and post-marketing studies to support payer discussions and value-based contracting.

Additionally, embrace flexible trial methodologies such as adaptive designs and decentralized elements to accelerate enrollment and gather broader patient data while reducing cost and time to insight. Strengthen commercialization readiness through early stakeholder mapping, channel optimization for hospital and retail pharmacy pathways, and tailored regional launch plans that reflect local regulatory and payer requirements. Finally, pursue targeted collaborations-whether through licensing, co-development, or commercial partnerships-to extend geographic reach, accelerate scale-up, and combine complementary scientific assets. These actions collectively reduce execution risk and enable organizations to translate molecular advances into sustainable therapeutic impact.

Transparent and reproducible research methodology combining primary interviews, literature synthesis, patent and clinical pipeline analysis, and scenario-based triangulation of insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to synthesize clinical, regulatory, and commercial intelligence into an actionable view. Primary research included structured interviews with clinical investigators, regulatory specialists, payer advisors, and supply chain executives to capture first-hand perspectives on trial design preferences, reimbursement expectations, and operational constraints. Secondary research reviewed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to triangulate development trends and historical regulatory precedents. Patent landscaping and clinical pipeline mapping informed assessments of mechanistic innovation and competitive density.

Data synthesis applied a triangulation approach to validate insights across independent sources, and scenario analysis was used to explore the operational implications of supply chain and policy shocks. Limitations are acknowledged, including the evolving nature of clinical data and policy changes that may shift the competitive landscape; accordingly, recommendations emphasize resilient, adaptable strategies rather than single-point predictions. The methodology prioritized reproducibility and transparency in assumptions, and where expert opinion supplemented public data, that synthesis was clearly flagged and cross-checked against available empirical evidence to ensure robustness.

Synthesis of strategic priorities showing how scientific innovation combined with operational resilience and evidence generation will determine long-term success in oncology

In conclusion, tyrosine kinase inhibitors remain a pivotal class of oncology therapeutics with continuous innovation driving both new clinical possibilities and heightened strategic complexity. Advances in molecular targeting, coupled with adaptive trial designs and an emphasis on real-world outcomes, are reshaping development paradigms and commercial expectations. External pressures such as trade policy shifts and supply chain vulnerabilities are compelling manufacturers to rethink sourcing strategies and to integrate resilience into their operational models. At the same time, regional regulatory divergence and evolving payer demands necessitate tailored access strategies that reconcile global evidence generation with local requirements.

Ultimately, organizations that align scientific differentiation with rigorous evidence generation, robust manufacturing planning, and region-specific commercialization readiness will be best positioned to convert therapeutic promise into clinical impact and sustainable business performance. Collaboration across clinical, regulatory, manufacturing, and commercial functions is essential, as is a willingness to adopt flexible development pathways and innovative contracting approaches that reflect the realities of modern oncology care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tyrosine Kinase Inhibitors Market, by Indication

  • 8.1. Breast Cancer
  • 8.2. Chronic Myeloid Leukemia
    • 8.2.1. First Line
    • 8.2.2. Second Line
    • 8.2.3. Third Line
  • 8.3. Non Small Cell Lung Cancer
    • 8.3.1. First Line
    • 8.3.2. Second Line
    • 8.3.3. Third Line
  • 8.4. Renal Cell Carcinoma

9. Tyrosine Kinase Inhibitors Market, by Target

  • 9.1. Alk
  • 9.2. Bcr-Abl
    • 9.2.1. First Generation
    • 9.2.2. Second Generation
    • 9.2.3. Third Generation
  • 9.3. EGFR
    • 9.3.1. First Generation
    • 9.3.2. Second Generation
    • 9.3.3. Third Generation
  • 9.4. Vegfr

10. Tyrosine Kinase Inhibitors Market, by Generation

  • 10.1. First Generation
  • 10.2. Second Generation
  • 10.3. Third Generation

11. Tyrosine Kinase Inhibitors Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Tyrosine Kinase Inhibitors Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Retail Pharmacies

13. Tyrosine Kinase Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Tyrosine Kinase Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Tyrosine Kinase Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Tyrosine Kinase Inhibitors Market

17. China Tyrosine Kinase Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Astellas Pharma Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Blueprint Medicines Corporation
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Eli Lilly and Company
  • 18.13. Exelixis, Inc.
  • 18.14. GlaxoSmithKline plc
  • 18.15. Incyte Corporation
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Pfizer Inc.
  • 18.19. Rigel Pharmaceuticals, Inc.
  • 18.20. Roche Holding AG
  • 18.21. Sanofi S.A.
  • 18.22. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ALK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGFR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 187. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 189. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 191. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 217. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 218. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 219. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 221. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 222. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 227. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 228. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 229. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 231. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 232. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. NATO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TARGET, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)